Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

被引：203

作者：

Gonzales, Andrea J. ^{[1
]}

Hook, Kenneth E. ^{[1
]}

Althaus, Irene W. ^{[1
]}

Ellis, Paul A. ^{[1
]}

Trachet, Erin ^{[1
]}

Delaney, Amy M. ^{[1
]}

Harvey, Patricia J. ^{[1
]}

Ellis, Teresa A. ^{[1
]}

Amato, Danielle M. ^{[1
]}

Nelson, James M. ^{[1
]}

Fry, David W. ^{[1
]}

Zhu, Tong ^{[2
]}

Loi, Cho-Ming ^{[2
]}

Fakhoury, Stephen A. ^{[3
]}

Schlosser, Kevin M. ^{[3
]}

Sexton, Karen E. ^{[3
]}

Winters, R. Thomas ^{[3
]}

Reed, Jessica E. ^{[3
]}

Bridges, Alex J. ^{[3
]}

Lettiere, Daniel J. ^{[4
]}

Baker, Deborah A. ^{[4
]}

Yang, Jianxin ^{[4
]}

Lee, Helen T. ^{[3
]}

Tecle, Haile ^{[3
]}

Vincent, Patrick W. ^{[4
]}

机构：

[1] Pfizer Global Res & Dev, Canc Biol, Ann Arbor, MI USA

[2] Pfizer Global Res & Dev, Pharmacokinet & Drug Metab, Ann Arbor, MI USA

[3] Pfizer Global Res & Dev, Chem, Ann Arbor, MI USA

[4] Pfizer Global Res & Dev, Canc Biol, Groton, CT USA

来源：

MOLECULAR CANCER THERAPEUTICS | 2008年 / 7卷 / 07期

关键词：

D O I：

10.1158/1535-7163.MCT-07-2232

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Signaling through the erbB receptor family of tyrosine kinases contributes to the proliferation, differentiation, migration, and survival of a variety of cell types. Abnormalities in members of this receptor family have been shown to play a role in oncogenesis, thus making them attractive targets for anticancer treatments. PF-00299804 is a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor currently in phase I clinical trials. PF-00299804 is believed to irreversibly inhibit erbB tyrosine kinase activity through binding at the ATP site and covalent modification of nucleophilic cysteine residues in the catalytic domains of erbB family members. Oral administration of PF-00299804 causes significant antitumor activity, including marked tumor regressions in a variety of human tumor xenograft models that express and/or overexpress erbB family members or contain the double mutation (L858R/T790M) in erbB1 (EGFR) associated with resistance to gefitinib and erlotinib. Furthermore, PF-00299804 shows exceptional distribution to human tumor xenografts and excellent pharmacokinetic properties across species.

引用

页码：1880 / 1889

页数：10

共 48 条

[1] Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma [J].

Abd El-Rehim, DM ;

Pinder, SE ;

Paish, CE ;

Bell, JA ;

Rampaul, RS ;

Blamey, RW ;

Robertson, JFR ;

Nicholson, RI ;

Ellis, IO .

BRITISH JOURNAL OF CANCER, 2004, 91 (08) :1532-1542

[2]

ALIMANDI M, 1995, ONCOGENE, V10, P1813

[3] Critical update and emerging trends in epidermal growth factor receptor targeting in cancer [J].

Baselga, J ;

Arteaga, CL .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2445-2459

[4] Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models [J].

Chen, Jianping ;

Smith, Melissa ;

Kolinsky, Kenneth ;

Adames, Violeta ;

Mehta, Nila ;

Fritzky, Luke ;

Rashed, Mohammad ;

Wheeldon, Eric ;

Linn, Michael ;

Higgins, Brian .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (05) :651-659

[5] FDA drug approval summary:: Gefitinib (ZD1839) (Iressa®) tablets [J].

Cohen, MH ;

Williams, GA ;

Sridhara, R ;

Chen, G ;

Pazdur, R .

ONCOLOGIST, 2003, 8 (04) :303-306

[6] FDA drug approval summary:: Erlotinib (Tarceva®) tablets [J].

Cohen, MH ;

Johnson, JR ;

Chen, YF ;

Sridhara, R ;

Pazdur, R .

ONCOLOGIST, 2005, 10 (07) :461-466

[7]

CORBETT TH, 1977, CANCER, V40, P2660, DOI 10.1002/1097-0142(197711)40:5+<2660::AID-CNCR2820400940>3.0.CO

[8]

2-M

[9] INTERACTION OF THE NEU P185 AND EGF RECEPTOR TYROSINE KINASES - IMPLICATIONS FOR CELLULAR-TRANSFORMATION AND TUMOR-THERAPY [J].

DOUGALL, WC ;

QIAN, XL ;

GREENE, MI .

JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, 53 (01) :61-73

[10] PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib [J].

Engelman, Jeffrey A. ;

Zejnullahu, Kreshnik ;

Gale, Christopher-Michael ;

Lifshits, Eugene ;

Gonzales, Andrea J. ;

Shimamura, Takeshi ;

Zhao, Feng ;

Vincent, Patrick W. ;

Naumov, George N. ;

Bradner, James E. ;

Althaus, Irene W. ;

Gandhi, Leena ;

Shapiro, Geoffrey I. ;

Nelson, James M. ;

Heymach, John V. ;

Meyerson, Matthew ;

Wong, Kwok-Kin ;

Janne, Pasi A. .

CANCER RESEARCH, 2007, 67 (24) :11924-11932

← 1 2 3 4 5 →